Plasma phosphorylated tau at threonine 217 (p-tau217) is a robust marker of Alzheimer’s disease (AD) pathology and progression. However, individuals positive for p-tau217 show substantial clinical heterogeneity, suggesting the influence of modifying biological processes. Here, we investigated whether plasma glial...
B. Bellaver, G. Povala, P. C. L. Ferreira et al.· Molecular Neurodegeneration· 0 citations
These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.
Saima Rathore, E. Dammer, Anantharaman Shantaraman et al.· Molecular Neurodegeneration· 0 citations
GCH1 pathogenic variants were associated with a clinically distinct phenotype characterized by earlier disease onset and slower progression of motor complications, suggesting that GCH1 genetic variants may serve as genetic biomarkers for patient stratification and prognosis in PD.
J. Shin, M. T. Periñán, J. W. Jang et al.· medRxiv· 0 citations
PGS demonstrated clinically meaningful risk prediction for substance use disorders in EA and LA, supporting the feasibility of future clinical implementation for population-level screening and underscoring the urgent need for more genetic studies in that population.
Dong-Bing Lai, Michael Zhang, Tae-Hwi Schwantes-An et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
